Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.
NCT ID: NCT02653339
Last Updated: 2016-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
180 participants
INTERVENTIONAL
2016-06-30
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation
NCT04388358
Study on the Mechanism of ZhenQiFuZheng in the Treatment of Allergic Rhinitis Based on Intestinal Flora and Metabolites
NCT06427577
Effect of Qi-tonifying Chinese Herbal Products for Treatment of Allergic Rhinitis
NCT01631032
Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis
NCT02339714
Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis
NCT05901532
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Qufeng Shengshi Fang and Loratadine
Qufeng Shengshi Fang is a traditional Chinese medicine form 8 kinds of herbs. Loratadine is the second generation antihistamines, after converted into its active metabolite Carrie period (carebastine), its antihistamines and allergy effect has been demonstrated in vitro and in vivo tests, also received data from clinical trials.
Qufeng Shengshi Fang and Loratadine
The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.
The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD
Loratadine
The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.
The control group patients are treated with Loratadine by oral, 10mg QD
Loratadine
Loratadine (INN) is a second-generation H1 histamine antagonist drug used to treat allergies. In structure, it is closely related to tricyclic antidepressants, such as imipramine, and is distantly related to the atypical antipsychotic quetiapine.Loratadine is marketed by Schering-Plough\[needs update\] under several trade names (e.g., Claritin) and also by Shionogi in Japan. It is available as a generic drug and is marketed for its nonsedating properties. In a version named Claritin-D or Clarinase, it is combined with pseudoephedrine, a decongestant; this makes it useful for colds, as well as allergies but adds potential side effects of insomnia, anxiety, and nervousness.
Qufeng Shengshi Fang and Loratadine
The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.
The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD
Loratadine
The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.
The control group patients are treated with Loratadine by oral, 10mg QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Qufeng Shengshi Fang and Loratadine
The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.
The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD
Loratadine
The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.
The control group patients are treated with Loratadine by oral, 10mg QD
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* have allergic rhinitis in episodes.
* without antihistamine,local anaesthetic or traditional Chinese medicine in last months.
* signed the informed consent form.
Exclusion Criteria
* have nasal surgery or a history of cancer(tumor).
* have other serious illness or evidence of mental disorders.
* female in pregnancy and lactation
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaochun Liang, Doctor
Role: STUDY_DIRECTOR
Peking Union Medical College Hospital traditional Chinese medicine department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Union Medical College Hospital traditional Chinese medicine department
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JS-958
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.